Generic placeholder image

Current Neuropharmacology


ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Current Drug Managements of Wilson’s Disease: From West to East

Author(s): Wen-Jie Li, Chen Chen, Zhi-Fei You, Ren-Min Yang and Xiao-Ping Wang

Volume 14, Issue 4, 2016

Page: [322 - 325] Pages: 4

DOI: 10.2174/1570159X14666151130222427

Price: $65


Wilson’s disease (WD), also called hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism characterized by the multiple mutations in the ATP-ase 7B gene of chromosome 13q. About half of the WD patients have neurological or psychiatric symptoms. As WD is a kind of medicable or nearly curable neurodegenerative disease in the field of medicine, early consideration/examination and without delay/ life-long treatment usually lead to better prognoses. The drugs, also named as anticopper agents, are commonly used in clinics including D-penicillamine, trientine, sodium dimercaptosuccinate, dimercaptosuccinic acid, zinc and tetrathiomolybdate. This provides detailed reviews about these medicines.

Keywords: D-penicillamine, dimercaptosuccinic acid, hepatolenticular degeneration, sodium dimercaptosuccinate, tetrathiomolybdate, trientine, Wilson’s disease, zinc.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy